LGNXZ — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 51,812,000 | 43,554,000 | 3,143,000 | -7,172,000 | 941,774,000 | 72,307,000 | 111,335,000 |
| Dec 2023 | 32,868,000 | 24,630,000 | 3,078,000 | -10,273,000 | 787,216,000 | 22,954,000 | 86,303,000 |
| Dec 2022 | 59,221,000 | 50,653,000 | 12,341,000 | 404,000 | 762,668,000 | 45,006,000 | 165,183,000 |
| Dec 2021 | 64,835,000 | 53,008,000 | 15,706,000 | 13,723,000 | 1,297,590,000 | 19,522,000 | 476,431,000 |
Yahoo Snapshot (yfinance, live)
Total Revenue
$290,542,016
EBITDA
$133,011,000
Free Cash Flow
$139,748,880
Enterprise Value
—
Total Cash
$1,357,757,952
Total Debt
$1,131,453,056
Shares Out
—
Trailing EPS
—
Book Value
$49.79
ROE
22.0%
ROA
4.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 131,314,000 | 11,942,000 | 52,154,000 | 941,774,000 | 111,335,000 | — | — |
| Dec 2023 | 196,245,000 | 3,037,000 | -33,361,000 | 787,216,000 | 86,303,000 | — | — |
| Dec 2022 | 241,544,000 | 103,851,000 | 57,138,000 | 762,668,000 | 165,183,000 | — | — |
| Dec 2021 | 46,592,000 | -10,144,000 | 18,107,000 | 1,297,590,000 | 476,431,000 | — | — |
| Dec 2020 | 120,282,000 | 807,076,000 | 629,302,000 | 1,362,285,000 | 652,760,000 | — | — |
| Dec 2019 | 43,484,000 | 13,746,000 | 666,337,000 | 1,494,915,000 | 727,683,000 | — | — |
| Dec 2018 | 56,157,000 | 37,041,000 | 45,279,000 | 1,260,803,000 | 699,889,000 | — | — |
| Dec 2017 | 56,157,000 | 37,041,000 | 45,279,000 | 671,021,000 | 252,374,000 | — | — |
| Dec 2016 | 29,648,000 | 15,096,000 | 6,608,000 | 601,585,000 | 230,732,000 | — | — |
| Dec 2015 | 14,602,000 | 3,349,000 | 754,000 | 503,061,000 | 226,151,000 | — | — |
TTM Snapshot
Revenues TTM
$169,360,000
NetIncome TTM
$-34,890,000
OpCashFlow TTM
$0
Assets (Latest)
$941,774,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.11T | $1246.93 | — |
| JNJ | JOHNSON & JOHNSON | $658.00B | $273.04 | — |
| ABBV | AbbVie Inc. | $467.44B | $264.52 | — |
| MRK | Merck & Co., Inc. | $371.70B | $150.66 | — |
| NVSEF | NOVARTIS AG | $310.96B | $163.60 | — |
News headlines (Yahoo Finance, 1h cache)
Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock
2026-08-14 20:02 · Yahoo
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run
2026-08-14 11:11 · Yahoo
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced?
2026-08-13 21:09 · Yahoo
Ligand (LGND) Q2 2026 Earnings Call Transcript
2026-08-13 13:13 · Yahoo
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
2026-08-10 20:12 · Yahoo
LGND: XOMA Acquisition Closed
2026-08-10 09:27 · Yahoo
Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ...
2026-08-06 23:18 · Yahoo
Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary
2026-08-06 22:40 · Yahoo
Ligand Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 21:03 · Yahoo
This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking Zone
2026-08-06 20:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.